Open AccessMometasone Furoate in Patients with Eosinophilic Esophagitis
Author(s) -
Bergquist Henrik,
Larsson Helen,
Johansson Leif,
Bove Mogens
Publication year - 2011
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599811416318a129
Subject(s) - mometasone furoate , eosinophilic esophagitis , medicine , dysphagia , esophagitis , placebo , gastroenterology , adverse effect , quality of life (healthcare) , corticosteroid , surgery , disease , pathology , alternative medicine , nursing , reflux
Objective The treatment of patients with eosinophilic esophagitis remains challenging. The effects of the current first‐choice treatment, ie, topical corticosteroids, are still inadequately surveyed. Our aim was to assess dysphagia and health‐related quality of life using validated scales and questionnaires before and after treatment with mometasone furoate. Method Newly diagnosed, untreated adult patients with eosinophilic esophagitis were included and given 200 µg of orally administered topical mometasone furoate 4 times daily. Questionnaires, incorporating the Watson Dysphagia Scale, the EORTC QLQ‐OES18, and the SF‐36, were completed before and after 2 months of treatment. Results Thirty‐one consecutive patients (22 males, mean age 45, range 18‐89) completed the trial. At inclusion, the mean scores of the Watson Dysphagia Scale, the EORTC QLQ‐OES18 dysphagia scale, eating scale and choking item, and the SF‐36 global health dimension and social functioning dimension were 21.3, 20.4, 35.0, 38.6, 71.1, and 82.3, respectively. Posttreatment, these scores improved to 8.9 ( P <. 0001), 4.6 ( P <. 00001), 17.8 ( P <. 001), 16.0 ( P <. 01), 76.1 ( P <. 05) and 91.9 ( P =. 0001), respectively. Except for one case of oral candidiasis, no significant side effects were reported. Conclusion Treatment with 2 months of orally administered mometasone furoate seems to have a beneficial effect on dysphagia and health‐related quality of life in the majority of adult patients with eosinophilic esophagitis. However, a randomized placebo‐controlled trial is warranted in order to verify this.